Vanda Pharmaceuticals has launched NEREUS™ (tradipitant), the first new prescription drug in over 40 years for preventing motion sickness-induced vomiting in adults. Approved by the FDA in December 2025, NEREUS™ works by blocking NK-1 receptors in the brain to stop vomiting triggered by motion. It is available nationwide through pharmacies and a direct-to-consumer platform at nereus.us, offering a discounted price of $85 per dose compared to the standard $255. This new treatment addresses a common condition affecting up to 30% of American adults during travel and represents a significant advancement in motion sickness care.
Agora, Inc. announced its Q1 2026 financial results with revenues rising 13.5% to $37.7 million and net income increasing to $1.1 million, marking its sixth consecutive quarter of GAAP profitability. The company launched Agent Studio, a no-code platf...
TIFIN.AI has launched TIFIN Australia, a new joint venture aimed at bringing advanced AI technology to the Australian wealth management market. Led by experienced executives Marcus Price and Justin Schmitt, the platform will offer AI-native solutions...
Webco Industries reported a net income of $8.0 million for Q3 fiscal 2026, up from $5.0 million the previous year, driven by a 15.6% increase in net sales to $179.6 million. The company also saw improved gross profit margins and increased operating i...
SpaceX is set for a massive IPO with a valuation between $1.5 trillion and $1.75 trillion, but it does not meet key S&P 500 inclusion criteria such as profitability, public float, and trading history. Market strategist Jay Woods argues against changi...
Vestand Inc. received a Nasdaq Staff Delisting Determination due to its failure to file required financial reports (10-Q and 10-K) on time. The company has requested a hearing to appeal this decision and is working to file the overdue reports promptl...
